Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabatolimab plus azacitidine and venetoclax in newly diagnosed AML patients unfit for intensive chemotherapy
jRCT2021210050Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of sabatolimab, venetoclax and azacitidine in acute myeloid leukemia (AML), sponsored by Novartis. Primary endpoints: Incidence of dose-limiting toxicities and Complete remission rate. Started Nov 2021; status: completed.
02
Drugs
sabatolimabvenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2021210050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210050.